NCT07685808ClinicalTrials.gov
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity
En resumen
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…
Fase 2360 participantes buscados22 centros1 país
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07685808Abrir este registro en ClinicalTrials.govSincronizado anteayer
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 360 participants (target), run at 22 sites.
How this score is built
- Enrolment25/40
360 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration6/10
Planned over about 18 months
- Sponsor scale9/10
Regeneron Pharmaceuticals has led 250 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Afecciones
- Overweight or Obesity
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 2 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | QUADRUPLE (4) |
| Inscripción | 360 participantes buscados |
Patrocinador y colaboradores
- Regeneron Pharmaceuticals Patrocinador
Grupos e intervenciones
- Olatorepatide arm 1EXPERIMENTAL
- Olatorepatide arm 2EXPERIMENTAL
- Olatorepatide arm 3EXPERIMENTAL
- Olatorepatide arm 4EXPERIMENTAL
- Olatorepatide arm 5EXPERIMENTAL
- Matching Placebo arm 6ACTIVE_COMPARATOR
Intervenciones
- Fármaco Olatorepatide
Administered per the protocol
- Fármaco Placebo
Administered per the protocol
Variables de resultado
Variable de resultado principal
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Plazo Up to approximately 60 weeks
Variable de resultado principal
Severity of TEAEs
Plazo Up to approximately 60 weeks
Variable de resultado principal
Percent change in body weight
Plazo From baseline to week 52
Variable de resultado secundaria
Olatorepatide concentrations
Plazo Up to approximately 60 weeks
Variable de resultado secundaria
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
Plazo Up to approximately 52 weeks
Variable de resultado secundaria
Magnitude of ADA to olatorepatide
Plazo Up to approximately 52 weeks
Fechas
| Fecha de inicio | 28 de julio de 2026 (real) |
|---|---|
| Finalización principal | 21 de enero de 2028 (estimada) |
| Finalización | 21 de enero de 2028 (estimada) |
| Primera publicación | 6 de julio de 2026 (real) |
| Última actualización | 18 de noviembre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | noviembre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
22 centros están en reclutamiento
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Flourish Research, Ravenswood Rheumatology | Chicago | Illinois | En reclutamiento |
| Charter Research LLC - Chicago | Chicago | Illinois | En reclutamiento |
| Alliance for Multispecialty Research (AMR) Clinical Miami | Doral | Florida | En reclutamiento |
| AMR Clinical - Fort Myers | Fort Myers | Florida | En reclutamiento |
| Tribe Clinical Research | Greenville | South Carolina | En reclutamiento |
| AGA Clinical Trials | Hialeah | Florida | En reclutamiento |
| Flourish Research, Nature Coast Clinical Research | Inverness | Florida | En reclutamiento |
| Flourish Research, Jacksonville Center for Clinical Research | Jacksonville | Florida | En reclutamiento |
| AMR Clinical - Lexington | Lexington | Kentucky | En reclutamiento |
| K2 Medical Research Maitland LLC, Main Office | Maitland | Florida | En reclutamiento |
| AMR Clinical - Mobile | Mobile | Alabama | En reclutamiento |
| NYC Research Inc | New York | New York | En reclutamiento |
| AMR Clinical - Chicago Oak Brook | Oak Brook | Illinois | En reclutamiento |
| Velocity Clinical Research - Omaha | Omaha | Nebraska | En reclutamiento |
| Rochester Clinical Research | Rochester | New York | En reclutamiento |
| Flourish Research, Legacy Oaks Tower | San Antonio | Texas | En reclutamiento |
| The IMA Group, IMA Clinical Research St. Petersburg | St. Petersburg | Florida | En reclutamiento |
| Charter Research LLC - The Villages | The Villages | Florida | En reclutamiento |
| Diablo Clinical Research - Flourish Research | Walnut Creek | California | En reclutamiento |
| Chase Medical Research | Waterbury | Connecticut | En reclutamiento |
| AMR Clinical Wichita | Wichita | Kansas | En reclutamiento |
| Clinical Site Partners, LLC DBA Flourish Research | Winter Park | Florida | En reclutamiento |
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 18 de noviembre de 2026
Centro añadido
1 site added (22 total)
2122
- 13 de octubre de 2026
Centro añadido
3 sites added (21 total)
1821
- 29 de septiembre de 2026
Centro añadido
13 sites added (18 total)
518
- 20 de agosto de 2026
Estado modificado
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 20 de agosto de 2026
Reclutamiento abierto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 20 de agosto de 2026
Centro añadido
5 sites added (5 total)
05